DNA X, Inc.
For the period ended Dec 31, 2025. Filed Apr 15, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 15, 2026
SONM$2.22+4.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements and Supplementary Data
Item 8. Financial Statements and Supplementary Data
The following consolidated financial statements of DNA X, Inc., and the independent registered public accounting firm’s report are incorporated by reference from Part IV, Item 15(1) and (2):
| Report of Independent Registered Public Accounting Firm (Baker Tilly LLP, Campbell, California, PCAOB ID: 23) | F-1 |
|---|---|
| Consolidated Balance Sheets – At December 31, 2025 and 2024 | F-2 |
| Consolidated Statements of Operations – Years Ended December 31, 2025 and 2024 | F-3 |
| Consolidated Statements of Stockholders’ Equity – Years Ended December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Cash Flows – Years Ended December 31, 2025 and 2024 | F-5 |
| Notes to the Consolidated Financial Statements | F-6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.